The antibody discovery team at Twist bets on mouse model player in a boost to its portfolio
Twist Bioscience has come a long way since dipping its toes into the antibody discovery space a couple years ago, spinning out its first company just last week to take a Covid-19 antibody into the clinic. There’s plenty more where that came from, CEO Emily Leproust says — and she thinks a small biotech’s mice are the key to getting there.
Leproust is putting down up to $10 million in cash and another $140 million in stock to buy out Massachusetts-based Abveris (formally known as AbX Biologics) and its family of hyperimmune mouse models, she announced on Monday morning. If Abveris hits an internal revenue target next year, it’s eligible for up to another $40 million in Twist shares.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
